Physician profile
Jeffrey E Moore
NPI 1366493405
$2,645.50
in general payments reported to CMS, 2019-2025
29 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,352 · 2020: $265 · 2021: $223 · 2022: $340 · 2023: $414 · 2024: $51.38.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $465.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $465.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $315.79 | 2019-2023 | Mounjaro, Emgality, Jardiance |
| Glaxosmithkline, LLC. | $297.02 | 2019-2023 | Trelegy Ellipta, Shingrix, Arexvy |
| Astrazeneca Pharmaceuticals Lp | $263.77 | 2019-2021 | |
| Amgen INC. | $220.89 | 2019-2023 | Otezla, Repatha |
| Pfizer INC. | $198.07 | 2019-2023 | |
| Amarin Pharma, INC. | $165.73 | 2019-2021 | |
| Abbvie INC. | $154.41 | 2021-2024 | |
| Merck Sharp & Dohme LLC | $151.80 | 2019-2023 | Gardasil 9, Vaxelis, Vaxneuvance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $115.85 | 2019-2023 | Xifaxan |
| Novartis Pharmaceuticals Corporation | $82.42 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $72.92 | 2019 | |
| Sanofi-Aventis U.S. LLC | $67.92 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $66.91 | 2019-2022 | |
| Abbott Laboratories | $56.91 | 2021-2023 | Freestyle Libre 3 |
| Novo Nordisk INC | $54.03 | 2019-2023 | Wegovy |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $49.57 | 2022-2023 | Veozah, Myrbetriq |
| Allergan, INC. | $44.29 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $41.68 | 2022 | |
| Medtronic, INC. | $40.84 | 2021-2023 | Inpen Smart Insulin Delivery System |
| Boehringer Ingelheim Pharmaceuticals, INC. | $31.18 | 2020-2022 | |
| Axsome Therapeutics, INC. | $22.47 | 2023 | Auvelity |
| Dexcom, INC. | $19.68 | 2023 | Dexcom G6 Transmitter |
| Genentech USA, INC. | $19.13 | 2019 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $18.80 | 2022 | |
| Cranial Technologies, INC | $18.26 | 2023 | Doc Band |
| Mylan Specialty L.P. | $16.32 | 2019 | |
| Evoke Pharma, INC. | $13.68 | 2022 | |
| Jazz Pharmaceuticals INC. | $13.16 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $12.00 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Moore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.